Research programme: G protein-coupled receptor agonists - Galapagos/Ferring

Drug Profile

Research programme: G protein-coupled receptor agonists - Galapagos/Ferring

Alternative Names: G protein-coupled receptor agonists - Ferring/BioFocus; GPCR agonists - BioFocus/Ferring; GPCR agonists - Ferring/BioFocus; Research programme: women's health therapeutics - Galapagos/Ferring

Latest Information Update: 22 Feb 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals; Galapagos NV
  • Class
  • Mechanism of Action G protein-coupled receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Female genital diseases

Most Recent Events

  • 22 Feb 2010 Discontinued - Preclinical for Gynaecological disorders in United Kingdom (PO)
  • 04 Nov 2005 BioFocus has been acquired and merged into Galapagos NV
  • 16 Dec 2003 Preclinical trials in Gynaecological disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top